HopeStage
Back to all studies
TerminatedNCT01122927

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolarity type I, Manic or Mixed Episode With or Without Psychotic Features.

Medication studyAges 10–17Multiple countries
The study in practice

Understand this study

Who could participate?

Listed age limits: 10 years to 17 years.

What will I do during this study?

The study group receives aripiprazole as a study medication.

Listed locations
Dothan and 100 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateJuly 2010
Recruitment status
Terminated
Enrollment listed in the registry
524
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Bulgaria, Croatia, ...
Age range
From 10 Years to 17 Years
Official registry ID
NCT01122927
Official title
Show the full official title

A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia or Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

Recruitment & locations

Terminated

Dothan, United States · Downey, United States · Miami, United States

87 more locations
  • Atlanta, United States
  • Smyrna, United States
  • Oak Brook, United States
  • Wichita, United States
  • Minneapolis, United States
  • Buffalo, United States
  • Stony Brook, United States
  • Chapel Hill, United States
  • Cincinnati, United States
  • Cleveland, United States
  • Oklahoma City, United States
  • Philadelphia, United States
  • Houston, United States
  • San Antonio, United States
  • The Woodlands, United States
  • Richmond, United States
  • Bellevue, United States
  • Bothell, United States
  • Milwaukee, United States
  • Burgas, Bulgaria
  • Pazardzhik, Bulgaria
  • Plovdiv, Bulgaria
  • Rousse, Bulgaria
  • Sofia, Bulgaria
  • Targovishte, Bulgaria
  • Varna, Bulgaria
  • Rijeka, Croatia
  • Zagreb, Croatia
  • Budapest, Hungary
  • Gyula, Hungary
  • Szeged, Hungary
  • Vijayawada, India
  • Visakhapatnam, India
  • Ahmedabad, India
  • Maninagar, Ahmedabad, India
  • Mangalore, India
  • Calicut, India
  • Nashik, India
  • Ludhiana, India
  • Jaipur, India
  • Chennai, India
  • Maduri, India
  • Kanpur, India
  • Lucknow, India
  • Varanasi, India
  • Guntur, India
  • Kuala Lumpur, Malaysia
  • Dasmariñas, Philippines
  • Manila, Philippines
  • Iloilo City, Philippines
  • Mandaluyong, Philippines
  • Bialystok, Poland
  • Gdansk Wrzeszcz, Poland
  • Torun, Poland
  • Wroclaw, Poland
  • Cluj-Napoca, Romania
  • Timișoara, Romania
  • Bucharest, Romania
  • Craiova, Dolj, Romania
  • Iași, Romania
  • Nizhny Novgorod, Russia
  • Novosibirsk, Russia
  • Tonnelnyi Township, Russia
  • Kazan', Russia
  • Lipetsk, Russia
  • Moscow, Russia
  • Orenburg Region, Russia
  • Petrozavodsk, Russia
  • Saint Petersburg, Russia
  • Saratov, Russia
  • Tomsk, Russia
  • Yaroslavl, Russia
  • Yekaterinburg, Russia
  • Belgrade, Serbia
  • Novi Sad, Serbia
  • Taipei, Taiwan
  • Dnipro, Ukraine
  • Donetsk, Ukraine
  • Kharkiv, Ukraine
  • Kherson, Ukraine
  • Luhansk, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Simferopol Crimea, Ukraine
  • Temopil, Ukraine
  • Vinnytsia, Ukraine
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including Aripiprazole.

Who can participate?

Listed age limits: 10 years to 17 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies